Vol 71, No 6 (2020)
Original paper
Published online: 2020-12-02
Assessing the blood concentration of new adipocytokines in patients with ischaemic stroke
Abstract
Introduction: Ischaemic stroke (IS) is a disease that is a common cause of death and one of the most common causes of disability in adults. There is a continuous need to conduct stroke pathogenesis studies. A certain role here can be attributed to adipose-derived hormones. The aim of this paper is to assess the blood concentration for selected adipocytokines: omentin-1, irisin, protein-1 related with C1q/TNF (CTRP1), vaspin and nesfatin-1 in IS patients, and an attempt to define their role as risk factors for ischaemic stroke.
Material and methods: The study included 46 patients with ischaemic stroke (27 females, 19 males, average 67.6 years of age). The control group consisted of 32 patients (16 females, 16 males, average 64.1 years of age) who had never had cerebrovascular diseases.
Results: The concentration of omentin-1 and CTRP1 in the group of stroke patients was higher than in the control group, whereas the concentrations of nesfatin-1 and irisin was significantly lower than in the control group. The vaspin level was similar in both groups of patients. Statistical analysis using logistic regression allows us to find that CTRP1 can be a significant stroke risk factor. A statistically significant positive correlation was found between the concentration of CTRP1 and NIHSS. However, no correlation between the concentration of other adipocytokines under investigation and the severity of ischaemic stroke was found.
Conclusions: From among the adipocytokines under investigation, higher concentrations of omentin-1 and CTRP1 and lower blood concentrations of nesfatin-1, irisin significantly increase the odds of getting to the group of ischaemic patients. It seems that CTRP1 can be an independent predictive factor of IS.
Keywords: ischaemic strokeadipocytokinesomentin-1nesfatin-1CTRP1irisinvaspin
References
- Łabuz-Roszak B, Starostka-Tatar A, Lasek-Bal A, et al. Diagnostics, treatment and secondary prevention of ischemic stroke in the Silesian Province, Poland between 2009 and 2015. Neurol Neurochir Pol. 2018; 52(2): 235–242.
- Chwalba A, Machura E, Ziora K, et al. The role of adipokines in the pathogenesis and course of selected respiratory diseases. Endokrynol Pol. 2019; 70(6): 504–510.
- Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004; 89(6): 2548–2556.
- Baranowska-Bik A, Kalisz M, Martyńska L, et al. Plasma adiponectin array in women with Alzheimer's disease. Endokrynol Pol. 2018; 69(5): 550–559.
- Prugger C, Luc G, Haas B, et al. PRIME Study Group. Adipocytokines and the risk of ischemic stroke: the PRIME Study. Ann Neurol. 2012; 71(4): 478–486.
- Głogowska-Szeląg J, Kos-Kudła B, Marek B, et al. Assessment of selected adipocytokines in obese women with postmenopausal osteoporosis. Endokrynol Pol. 2019; 70(6): 478–483.
- Olszanecka-Glinianowicz M, Kocełak P, Orlik B, et al. Nowe adipokiny — korzystne czy niekorzystne w aspekcie patogenezy insulinooporności? Endokr Otył Zab Przem Mat. 2009; 5(4): 236–242.
- de Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007; 56(6): 1655–1661.
- Pukajło K, Kolackov K, Łaczmański Ł, et al. [Irisin — a new mediator of energy homeostasis]. Postepy Hig Med Dosw (Online). 2015; 69: 233–242.
- Jeong E, Youn BS, Kim DW, et al. Circadian rhythm of serum vaspin in healthy male volunteers: relation to meals. J Clin Endocrinol Metab. 2010; 95(4): 1869–1875.
- Blüher M. Vaspin in obesity and diabetes: pathophysiological and clinical significance. Endocrine. 2012; 41(2): 176–182.
- Shimizu H, Oh-I S, Hashimoto K, et al. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology. 2009; 150(2): 662–671.
- Szlachcic A, Surmiak M, Majka J, et al. Nesfatin-1: a new hormone in the control of food intake and the mechanism of damage and protection of gastric mucosa. Gastroenterol Rev. 2012; 6: 339–350.
- Schäffler A, Buechler C. CTRP family: linking immunity to metabolism. Trends Endocrinol Metab. 2012; 23(4): 194–204.
- Kazimierczak-Kabzińska A, Kajdaniuk D, Siemińska L, et al. Selected adipose tissue hormones in the blood of patients with ischaemic cerebral stroke. Endokrynol Pol. 2020; 71(1): 21–26.
- Bienek R, Marek B, Kajdaniuk D, et al. Adiponectin, leptin, resistin and insulin blood concentrations in patients with ischaemic cerebral stroke. Endokrynol Pol. 2012; 63(5): 338–345.
- Shang FJ, Wang JP, Liu XT, et al. Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Biomarkers. 2011; 16(8): 657–662.
- Shibata R, Ouchi N, Takahashi R, et al. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr. 2012; 4(1): 37.
- Yoo HJ, Hwang SY, Hong HoC, et al. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol. 2011; 10: 103.
- Zhong X, Zhang Hy, Tan H, et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin. 2011; 32(7): 873–878.
- Wu DM, Wang S, Wen X, et al. Impact of serum omentin-1 levels on functional prognosis in nondiabetic patients with ischemic stroke. Am J Transl Res. 2019; 11(3): 1854–1863.
- Xu T, Zuo P, Cao L, et al. Omentin-1 is Associated with Carotid Plaque Instability among Ischemic Stroke Patients. J Atheroscler Thromb. 2018; 25(6): 505–511.
- Huh JY, Siopi A, Mougios V, et al. Irisin in response to exercise in humans with and without metabolic syndrome. J Clin Endocrinol Metab. 2015; 100(3): E453–E457.
- Moraes C, Leal VO, Marinho SM, et al. Resistance exercise training does not affect plasma irisin levels of hemodialysis patients. Horm Metab Res. 2013; 45(12): 900–904.
- Norheim F, Langleite TM, Hjorth M, et al. The effects of acute and chronic exercise on PGC-1α, irisin and browning of subcutaneous adipose tissue in humans. FEBS J. 2014; 281(3): 739–749.
- Chen Jq, Huang Yy, Gusdon AM, et al. Irisin: a new molecular marker and target in metabolic disorder. Lipids Health Dis. 2015; 14: 2.
- Anastasilakis AD, Koulaxis D, Kefala N, et al. Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy. Metabolism. 2017; 73: 1–8.
- Zhang M, Chen P, Chen S, et al. The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study. Eur Rev Med Pharmacol Sci. 2014; 18(11): 1567–1572.
- Emanuele E, Minoretti P, Pareja-Galeano H, et al. Serum irisin levels, precocious myocardial infarction, and healthy exceptional longevity. Am J Med. 2014; 127(9): 888–890.
- Li DJ, Li YH, Yuan HB, et al. The novel exercise-induced hormone irisin protects against neuronal injury via activation of the Akt and ERK1/2 signaling pathways and contributes to the neuroprotection of physical exercise in cerebral ischemia. Metabolism. 2017; 68: 31–42.
- Jin Z, Guo P, Li X, et al. Neuroprotective effects of irisin against cerebral ischemia/ reperfusion injury via Notch signaling pathway. Biomed Pharmacother. 2019; 120: 109452.
- Tu WJ, Qiu HC, Cao JL, et al. Decreased Concentration of Irisin Is Associated with Poor Functional Outcome in Ischemic Stroke. Neurotherapeutics. 2018; 15(4): 1158–1167.
- Li Q, Chen R, Moriya J, et al. A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity. J Int Med Res. 2008; 36(4): 625–629.
- Youn BS, Klöting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008; 57(2): 372–377.
- Klöting N, Kovacs P, Kern M, et al. Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. Diabetologia. 2011; 54(7): 1819–1823.
- Gulcelik NE, Karakaya J, Gedik A, et al. Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol. 2009; 160(1): 65–70.
- Li HL, Peng WH, Cui ST, et al. Vaspin plasma concentrations and mRNA expressions in patients with stable and unstable angina pectoris. Clin Chem Lab Med. 2011; 49(9): 1547–1554.
- Aust G, Richter O, Rohm S, et al. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis. 2009; 204(1): 262–266.
- Kadoglou NPE, Fotiadis G, Lambadiari V, et al. Serum levels of novel adipokines in patients with acute ischemic stroke: potential contribution to diagnosis and prognosis. Peptides. 2014; 57: 12–16.
- Cura HS, Özdemir HH, Demir CF, et al. Investigation of vaspin level in patients with acute ischemic stroke. J Stroke Cerebrovasc Dis. 2014; 23(3): 453–456.
- Yosten GLC, Samson WK. Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol. 2009; 297(2): R330–R336.
- Dai H, Li X, He T, et al. Decreased plasma nesfatin-1 levels in patients with acute myocardial infarction. Peptides. 2008; 46: 167–171.
- Kuyumcu MS, Kuyumcu A, Yayla Ç, et al. Nesfatin-1 levels in patients with slow coronary flow. Kardiol Pol. 2018; 76(2): 401–405.
- Ding S, Qu W, Dang S, et al. Serum nesfatin-1 is reduced in type 2 diabetes mellitus patients with peripheral arterial disease. Med Sci Monit. 2015; 21: 987–991.
- Kuyumcu A. The relationship between nesfatin-1 and carotid artery stenosis. Scand Cardiovasc J. 2018; 52(6): 328–334.
- Erfani S, Moghimi A, Aboutaleb N, et al. Protective effects of Nesfatin-1 peptide on cerebral ischemia reperfusion injury via inhibition of neuronal cell death and enhancement of antioxidant defenses. Metab Brain Dis. 2019; 34(1): 79–85.
- Jeon JHo, Kim Ky, Kim JH, et al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J. 2008; 22(5): 1502–1511.
- Tang JN, Shen DL, Liu CL, et al. Plasma levels of C1q/TNF-related protein 1 and interleukin 6 in patients with acute coronary syndrome or stable angina pectoris. Am J Med Sci. 2015; 349(2): 130–136.
- Lu L, Zhang RY, Wang XQ, et al. C1q/TNF-related protein-1: an adipokine marking and promoting atherosclerosis. Eur Heart J. 2016; 37(22): 1762–1771.
- Muendlein A, Leiherer A, Saely C, et al. The novel adipokine CTRP1 is significantly associated with the incidence of major adverse cardiovascular events. Atherosclerosis. 2019; 286: 1–6.
